Continuous Glucose Monitoring in the Intensive Care Unit

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-20

Study Completion Date

2025-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the proposed clinical trial is to study the use of the Dexcom G7 continuous glucose monitor (CGM) within the intensive care unit (ICU) environment. The overall goal is to validate the accuracy and practicality of the Dexcom G7 when used to assess glycemia in critically ill patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Accuracy of CGM in the ICU, Compared to Standard of Care

NCT04352907

Diabetes

UNKNOWN

Continuous Glucose Monitoring in Intensive Care Unit

NCT05585801

Blood Glucose Critical Care

RECRUITING NA

The Performance of Dexcom G6 Glucose Monitoring in Critically Ill Patients

NCT05255783

Blood Glucose Humans Critical Care

COMPLETED NA

Expanding Use of CGM in Critical Care: Impact on Nurse Work Patterns and Patient Outcomes

NCT05571397

Hyperglycemia

COMPLETED PHASE1/PHASE2

Continuous Glucose Monitoring System: Accuracy and Prognostic Value in Critically Ill Patients

NCT07108179

Critically Ill Patients

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The specific goals are 1) to work with intensive care unit (ICU) staff, in a respiratory ICU setting, to determine how best to place and maintain Dexcom G7 continuous glucose monitors (CGMs) on patients and how to place recording devices and chargers in that environment, 2) download CGM readings to the Dexcom Dashboard in an analyzable format, and 3) to compare simultaneous CGM readings with glucose measurements obtained in the course of routine care as recorded in the electronic medical record. The primary analytical goal is the correlation of CGM glucose measurements with those obtained in the course of routine care. A secondary goal is to determine the frequency of device malfunctions that occur either as a result of device failure (e.g. it falls off) or adverse events (e.g. removal due to skin irritation).

Study subjects will be patients admitted to the 6-ICU UMass Memorial Medical Center (UMMMC) University Campus medical intensive care unit for any reason who have known diabetes or who are hyperglycemic (blood glucose concentration ≥200 mg/dL) with diabetes that was previously undiagnosed or unrecognized. All enrolled volunteers will have a Dexcom G7 CGM place on the skin according to manufacturer's specifications. The devices will remain in place for 10 days or until discharge from the ICU

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Hyperglycemic patients admitted to an intensive care unit will have blood glucose concentration measured using current standard-of-care tests (fingerstick determinations and laboratory assays). Study participants will bel be asked to volunteer to permit concurrent glucose measurement using a Dexcom G7 continuous glucose monitor in order to determine the accuracy and feasibility of the latter. Only standard glucose measurements will be used for patient management.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm

All members of the arm will have a CGM place and glucose concentration downloaded.

Group Type EXPERIMENTAL

Dexcom G7 Continuous Glucose Monitor

Intervention Type DIAGNOSTIC_TEST

Continuous glucose monitor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexcom G7 Continuous Glucose Monitor

Continuous glucose monitor

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Campus medical intensive care unit for any reason who have known diabetes or who are hyperglycemic (blood glucose concentration ≥200 mg/dL) with diabetes that was previously undiagnosed or unrecognized.

* Persons with either type 1 or type 2 diabetes.
* Persons of either sex.
* Persons of any age over 18.
* Persons able to give informed consent or cognitively impaired adults whose legally authorized representative (LAR) can give informed consent.
* English or Spanish speaking adults.

Exclusion Criteria

* Persons unable to provide informed consent.
* Cognitively impaired persons whose LAR declines to provide informed consent.
* Patients receiving hydroxyurea, which interferes with sensor function.
* Patients receiving high dose acetaminophen (\> 4 gm/day), which interferes with sensor function.
* Anasarca affecting preferred areas for device placement (arm, upper buttocks, or thigh), which may interfere with sensor accuracy.
* Severe cachexia with absence of subcutaneous fat at preferred sensor placement sites, which might interfere with sensor accuracy.
* Persons who are pregnant.
* Prisoners.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No